Schott Pharma concluded its fiscal year 2025 with a 5.8% increase in revenue.

This amounted to a total revenue of €986.2 million, despite challenging market conditions.

Meanwhile, full-year EBITDA was up by 11.5% at €280.3 million.

This positive development was driven by the Drug Containment Solutions segment (DCS), where revenue increased 11.9% to €548.0 million.

Products such as sterile ready-to-use (RTU) cartridges and vials, as well as specialty vials for biologic drugs, performed particularly well.

EBITDA in the DCS segment rose to €127.5 million, marking an increase of 34.9% due to a favourable product mix and efficiency gains.

Schott Pharma CEO Andreas Reisse said: “Amid the challenging macroeconomic environment, Schott Pharma once again delivered excellent results, and we met our targets for both revenue and profitability.

“While our core solutions remain a very solid and profitable business, we have effectively continued to focus on increasing the revenue share of our high-value solutions through product innovation, capacity expansions, and strong partnerships.

“As we expect the market to remain difficult, we target a revenue growth of 2-5% for fiscal year 2026 and an EBITDA margin of around 27%.

“This represents a bridge year, as we anticipate market dynamics to pick up again going forward.”

Revenue in the Drug Delivery Systems (DDS) segment was at €438.8m, representing a slight decline of 1.3%.

The lower demand for polymer syringes was offset by the sustained high demand for prefillable glass syringes.

EBITDA decreased by 9.9% to €152.8 million, mainly due to lower utilisation as well as ramp-up costs for the new prefillable glass syringe manufacturing facility in Hungary.

Meanwhile, Schott Pharma's operating cash flow came in at €179.9 million in the reporting year, after €224.8 million in 2024.

This was mainly due to a higher working capital need and timing of tax payments, which more than offset the EBITDA improvement.

Investments

At €144.8 million, CAPEX was on par with the previous year's level, as the company continued to invest in capacity expansion.

Reinhard Mayer, CFO of Schott Pharma, said: “Over the last six years, we have invested around €800 million in our global manufacturing network, particularly for high-value solutions.”

In 2025, Schott Pharma launched several products addressing market trends, such as the increasing demand for solutions that enable the safe and easy self-administration of injectable drugs at home; the growing range of sensitive biologics; as well as the need for a more sustainable manufacturing and reliable supply of drugs and vaccines.

The portfolio additions include sterile large-volume syringes and cartridges made of glass and polymer.

In addition, the company opened a new production site in Serbia and celebrated the ground breaking for a new facility for sterile RTU cartridges in Hungary.